Alamar Biosciences, Inc. reported significant financial growth in its latest quarterly filing, with total revenue reaching $29.4 million for the three months ended June 30, 2026, an increase of 82% compared to $16.2 million in the same period last year. Product revenue, which includes sales from instruments and consumables, surged by 93% to $23.3 million, driven by a 35% increase in instrument sales and a remarkable 147% rise in consumables revenue. Service and other revenue also saw a 49% increase, totaling $6.2 million, primarily due to heightened demand for its Technology Access Program (TAP) services.
The company's operating expenses rose significantly, totaling $31.3 million for the quarter, up 89% from $16.5 million in the prior year. This increase was largely attributed to a 55% rise in research and development expenses, which reached $13.8 million, and a 129% increase in selling, general, and administrative expenses, totaling $17.4 million. The net loss for the quarter was $13.2 million, compared to a loss of $7.0 million in the same quarter of 2025, reflecting the company's ongoing investment in growth and expansion.
Alamar's operational metrics indicate a growing customer base, with over 300 customers across 25 countries and a cumulative installed base of over 100 ARGO HT instruments. The average annual consumable pull-through per instrument exceeded $400,000 for the year ended December 31, 2025. The company is also expanding its product offerings, with plans to submit a new ARGO HT/DX instrument for FDA marketing authorization in 2027. The company’s geographic reach includes direct sales in North America, Europe, and China, with distribution agreements in various regions, including Australia and parts of Asia.
The company completed its initial public offering (IPO) in April 2026, raising approximately $219.9 million in gross proceeds, which has bolstered its cash reserves to $250.1 million as of June 30, 2026. This financial position is expected to support ongoing operations and future growth initiatives. However, Alamar continues to face challenges, including reliance on government funding for research, competition in the proteomics market, and the need for continuous innovation in its product offerings. The company anticipates continued operating losses as it invests in scaling its operations and developing new technologies.
About Alamar Biosciences, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov